The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: An update

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 203-207

  Lastra Gonzalez, Guido ^b   Manrique Acevedo, Camila ^b   Sowers, James R ^a  

^a University of Missouri   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOSE; MINERALOCORTICOID; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; METABOLISM;

ALDOSTERONE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 52649115386     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0035-9     Document Type: Review

References (35)

1. Ford ES: Prevalence of the metabolic syndrome defined by International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745-2749.
2. De Ferranti SD, Gauvreau K, Ludwig DS, et al.: Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004, 110:2494-2497.
3. Umpierrez GE, Cante P, Smiley D, et al.: Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007, 30:1699-1703.
4. Manrique C, Lastra G, Whaley-Connell A, Sowers JR: Hypertension and the cardiometabolic syndrome. J Clin Hypertens 2005, 7:471-476.
5. Cooper SA, Whaley-Connell A, Habibi J, et al.: Reninangiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2009-H2023.
6. Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000, 35:1270-1277.
7. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Pbysiol 2007, 292:82-97.
8. Wei Y, Sowers JR, Nistala R, er al.: Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006, 281:35137-35146.
9. Urukawa H, Katsuki A, Sumida Y, et al.: Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 2003, 88:4673-4676.
10. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003, 52:1-8.
11. Connell JMC, Davies E: The new biology of aldosterone. J Endocrinol 2005, 186:1-20.
12. Funder JW: The nongenomic actions of aldosterone. Endocr Rev 2005, 26:313-321.
13. Schiffrin EL: Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318.
14. Campion J, Maestro B, Molero S, et al.: Aldosterone impairs insulin responsiveness in U-937 promonocytic cells via downregulation of its own receptor. Biochem Funct 2002, 20:237-245.
15. Corry DB, Tuck ML: The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003, 5:106-109.
16. Caprio M, Feve B, Claes A, et al.: Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185-2194.
17. Taniyama Y, Hitomi H, Shah A, et al.: Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. A theroscler Thromb Vasc Biol 2005, 25:1142-1147.
18. Callera GE, Touyz RM, Tostes RC, et al.: Aldosterone activates vascular p38MAP kinase and NADPH via c-Src. Hypertension 2005, 45:773-779.
19. Hitomi H, Kiyomoto H, Nishiyama A, et al.: Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750-755.
20. Conn JW: Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965, 273:1135-1143.
21. Expert Committee on the Diagnosis and: Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Supp; 1):S5-S20.
22. Goodfriend TL, Egan BM, Kelley DE: Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401-405.
23. Kidambi S, Kotchen JM, Grim CE, et al.: Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007, 49:704-711.
24. Bochud M, Nussberger J, Bovet P, et al.: Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239-245.
25. Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005, 16:104-107.
26. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ: Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999, 7:355-362.
27. Ikeda T, Gomi T, Hirawa N, et al.: Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension 1996, 27:1180-1186.
28. Colussi G, Catena C, Lapenna R, et al.: Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007, 30:2349-2354.
29. Catena C, Lapena R, Baroselli S, et al.: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457-3463.
30. Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
31. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of a1dosterone blockade in patients with nephropathy. Hypertension 2003, 41:64-68.
32. Joffe HV, Kwong RY, Gerhard-Herman MD, et al.: Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552-2558.
33. Mulatero P, Stowasser M, Loh KC, et al.: Increasing diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004, 89:1045-1050.
34. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
35. Pitt B, Remme WJ, Zannad F: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 48:1309-1321.